The U.S. Food and Drug Administration has advised Collegium Pharmaceutical that it will not be able to complete its review of the company's opioid painkiller, Xtampza, by the deadline set for Oct.12, according to an update from Collegium.
Collegium Pharmaceutical Says FDA Review Of Opioid Painkiller To Be Delayed
Tech Times - 13 Oct 2015 13:02
The U.S. Food and Drug Administration has advised Collegium Pharmaceutical that it will not be able to complete its review of the company's opioid painkiller, Xtampza, by the deadline set for Oct.12, according to an update from Collegium.
Share this Article
Recommended